Rheumatoid Arthritis Plasma
Rheumatoid Arthritis Plasma - Human plasma collected from IRB-consented donors with clinically confirmed rheumatoid arthritis, a systemic autoimmune disease, and processed within one day of collection. Ideal for analysing ACPA and rheumatoid factor, acute phase proteins, and TNF and IL-6 pathway mediators. Stratification by seropositive or seronegative status, disease activity, and treatment line available, with matched healthy controls. Bulk plasma is available.
| Lot # | Condition | Volume | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 74392 | Rheumatoid Arthritis | 1.0 ML | Hispanic/Latino | 69 | Female | 14 | $316.00 | |||
| 72661 | Rheumatoid Arthritis | 1.0 ML | Hispanic/Latino | 53 | Female |
Methotrexate 15mg PO Weekly, Folic Acid 1 mg POQD, Prednisone 5 mg, Famotidine 40mg POQD, Amlodipine 10 mgPOQD
|
25 | $316.00 | ||
| 74366 | Rheumatoid Arthritis | 1.0 ML | Other | 56 | Female | United States |
Enbrel sureclick once a week Colestipol 2 Grams twice daily Mirapex .125mg 3xs daily Nortriptyline 10mg twice daily Gabapentin 300mg 4xs daily Advair 500 1 puff twice daily Proair Respiclick 2puffs every 4hrs PRN Prolia injection once every 6 months Tramadol 50mg every 8hrs PRN Labetalol 100mg they've daily Myrbetriq 50mg XR daily Sucralfate twice daily Vicodin XR 7.5/325 ever 6 hrs PRN
|
20 | $316.00 | |
| 74320 | Rheumatoid Arthritis | 1.0 ML | Caucasian | 70 | Female | United States |
Actemra Infusion Q4W Pilocarpine BID Mycophenolate 750 mg BID Losartan 12.5 1x/day Omeprazole 20mg/1x day Atorvastatin 10mg 1x/day Famotidine 20MG 1x/day Amitriptyline 10 mg 2x day
|
18 | $316.00 | |
| 73348 | Rheumatoid Arthritis | 1.0 ML | Caucasian | 51 | Female | United States |
Rituximab infusions Q 6 months Vitamin D QD
|
15 | $316.00 | |
| 72655 | Rheumatoid Arthritis | 1.0 ML | Hispanic/Latino | 41 | Male | United States |
Advil PRN Or Tylenol arthritis
|
5 | $316.00 | |
| 71562 | Rheumatoid Arthritis | 1.0 ML | Caucasian | 63 | Male | United States |
Enbrel 50mL inj QW Atorvastatin 10mg QD Trazadone PRN
|
15 | $316.00 | |
| 71769 | Rheumatoid Arthritis | 1.0 ML | Caucasian | 69 | Female | United States |
2025: Rinvoq, leflunomide, prednisone taper as needed. Percocet, Lyrica, cymbalta, Losartan/50mg/QD Hydrochlorothiazide/50mg/QD Orphenadrine ER/100mg/BID Vitamin B12/QD Iron/QD Calcium citrate/BID
|
18 | $316.00 | |
| 71636 | Rheumatoid Arthritis | 1.0 ML | Asian/Pacific Islander | 55 | Female | United States |
Diagnosed RA 2017 Currently on Sulfasalazine Metformin 500mg BID Tried one other med for RA in Past when first diagnosed
|
7 | $316.00 | |
| 70828 | Rheumatoid Arthritis | 1.0 ML | Caucasian | 64 | Female | United States |
Levothyroxine 75mcg QD Omeprazole 20mg QD Lisinopril 5 mg QD Metoprolol 25mg QD Simvastatin 25 mg QD Duloxetine 60 mg QD Vitamin B12 500 mcg 1 QD Vitamin D3 1000 IU BID Symbicort 160/4.5 2 puffs BID Semaglutide injections Cuvitru sub Q Qweek Hx: Rituxan Covid 19 Vaccine: Moderna Methotrexate 2.5 mg 4 tabs QW (paused in treatment) Symbicort 160/4.5 2 puffs BID Calcium 500 +D 1 pill QD Levothyroxine 75 mg QD Bisoprolol 2.5-6.2-5 mg 1 QD Estradiol .01 cream QW Prolia 1 ml once every 6 months Lidocaine Patch QD PRN
|
11 | $316.00 |
Rheumatoid Arthritis Plasma for Autoimmune and Inflammation Research
Rheumatoid Arthritis Plasma is collected from IRB-consented donors clinically diagnosed with rheumatoid arthritis (RA) and processed within one day of collection to preserve labile analytes such as cytokines, proteins, and metabolites. Anticoagulant type and aliquot volume are configured per project and reported per lot. This plasma supports research into autoimmune and inflammatory biomarkers, acute phase proteins including CRP, and methods for predicting flares. Bulk plasma is available.
Why Plasma for Rheumatoid Arthritis Research
Rheumatoid arthritis is a systemic autoimmune disease. Although the joint is the principal target, the autoantibody response and the acute phase reaction are systemic, which is why circulating specimens carry genuine diagnostic and mechanistic information rather than being a proxy for the joint.
- Anti-citrullinated protein antibodies and rheumatoid factor are the defining serological markers of RA, and their presence separates seropositive from seronegative disease — groups that differ in prognosis and in erosive potential.
- ACPA can be detectable years before clinical arthritis develops, which makes circulating specimens the only practical material for research into the pre-clinical and at-risk phases of the disease.
- Citrullination by peptidylarginine deiminase enzymes generates the neoepitopes recognised by ACPA, and antibodies to these modified proteins are measurable in plasma.
- The systemic acute phase response — CRP and related proteins — is part of the formal disease activity assessment in RA, so plasma analytes map directly onto composite clinical scores.
- TNF, IL-6, and GM-CSF are established therapeutic targets in RA, and plasma allows the systemic component of these pathways to be measured before and after treatment.
- Because plasma is collected without a clotting step, it preserves coagulation-sensitive mediators and is the preferred matrix on many proteomic and multiplex cytokine platforms; paired serum and synovial fluid from the same donor allow systemic and joint compartments to be compared.
Donor Stratification Available
- Serological status: ACPA and rheumatoid factor positive or negative, with titre where documented
- Disease activity: composite score such as DAS28 or CDAI, and CRP or ESR band where recorded
- Disease duration: early versus established RA, and erosive versus non-erosive disease
- Treatment status: DMARD-naive, methotrexate or other conventional DMARD, TNF inhibitor, IL-6 receptor inhibitor, T cell costimulation blockade, anti-CD20, or JAK inhibitor
- Extra-articular manifestations where documented, including nodules and interstitial lung disease
- Smoking status, a well-established RA risk factor that interacts with genetic risk and ACPA positivity
- Matched healthy controls available, alongside comparator inflammatory arthritis cohorts
Product Features
- Research Use Only (RUO)
- Plasma collected from clinically confirmed RA donors
- Processed within one day of collection
- IRB-approved protocols and informed consent
- Anticoagulant type specified at order where inventory permits
- Custom aliquot volumes available upon request
- Volumes and lot-specific processing details reported per lot
De-identified Donor Data
- Verified RA diagnosis
- Demographic data: age, sex assigned at birth, race/ethnicity
- Donor-reported medications, allergies, and comorbidities
- Serology and disease activity data where available
- Additional RA-specific metadata available on request
Applications
- ACPA and rheumatoid factor assay development, calibration, and specificity testing
- Biomarker discovery and validation for disease activity and flare prediction
- Cytokine and inflammation profiling, including TNF and IL-6 pathway readouts
- Acute phase protein and complement analysis
- Proteomic and metabolomic characterisation of systemic autoimmune inflammation
- Treatment-response and pharmacodynamic research across biologic and JAK inhibitor classes
- Autoantibody repertoire and citrullinated antigen reactivity profiling
- Comparative studies against seronegative inflammatory arthritis and osteoarthritis cohorts
Other Rheumatoid Arthritis Specimen Types
- Rheumatoid Arthritis Serum
- Rheumatoid Arthritis Whole Blood
- Rheumatoid Arthritis PBMC
- Rheumatoid Arthritis Leukopak
- Rheumatoid Arthritis Synovial Fluid
- Rheumatoid Arthritis Bulk Plasma
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Rheumatoid arthritis plasma is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse other disease states and collection formats, visit our human plasma page.
Protocols & Documentation
-
Download
Plasma Isolation
Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Plasma
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.